Online inquiry

IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ505MR)

This product GTTS-WQ505MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Urticaria research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ505MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13251MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ3289MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ6968MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ6860MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ3097MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ2602MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ11277MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ14640MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW